11 – 20 of 23
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML
(
- Contribution to journal › Article
-
Mark
Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia
(
- Contribution to journal › Article
- 2016
-
Mark
Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence.
(
- Contribution to journal › Article
-
Mark
Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli
(
- Contribution to journal › Article
-
Mark
Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia
(
- Contribution to journal › Article
-
Mark
In vivo CYP3A activity and pharmacokinetics of imatinib in relation to therapeutic outcome in chronic myeloid leukemia patients.
(
- Contribution to journal › Article
-
Mark
Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.
(
- Contribution to journal › Article
- 2015
-
Mark
The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses
(
- Contribution to journal › Article
-
Mark
Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era
(
- Contribution to journal › Article
-
Mark
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
(
- Contribution to journal › Article